KOD
Kodiak Sciences Inc. NASDAQ Listed Oct 4, 2018$43.68
Mkt Cap $2.3B
52w Low $2.81
90.8% of range
52w High $47.84
50d MA $35.00
200d MA $22.30
P/E (TTM)
-10.2x
EV/EBITDA
-5.7x
P/B
14.9x
Debt/Equity
0.4x
ROE
-146.1%
P/FCF
-10.9x
RSI (14)
—
ATR (14)
—
Beta
2.40
50d MA
$35.00
200d MA
$22.30
Avg Volume
1.1M
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
1200 Page Mill Road · Palo Alto, CA 94304 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | AMC | -1.02 | -1.04 | -2.0% | 38.12 | +4.4% | +12.3% | +6.6% | +2.3% | +9.6% | +9.7% | — |
| Nov 13, 2025 | AMC | -1.07 | -1.16 | -8.4% | 18.87 | -2.3% | +3.4% | +5.1% | +1.9% | +3.5% | +3.8% | — |
| Aug 13, 2025 | AMC | -1.01 | -1.03 | -2.0% | 8.62 | +9.5% | +16.5% | +22.6% | +30.5% | +10.0% | +10.2% | — |
| May 14, 2025 | AMC | -0.89 | -1.09 | -22.5% | 3.94 | -3.0% | -15.5% | -11.2% | -5.8% | +3.0% | -10.2% | — |
| Mar 27, 2025 | AMC | -0.90 | -0.84 | +6.7% | 3.06 | -2.9% | -4.9% | -8.2% | -16.3% | -12.7% | -21.6% | — |
| Nov 14, 2024 | AMC | -0.90 | -0.84 | +6.7% | 5.30 | +0.8% | +4.3% | +6.8% | +6.4% | +9.2% | +11.3% | — |
| Aug 14, 2024 | AMC | -0.87 | -0.86 | +1.1% | 2.55 | +5.9% | +1.6% | -3.1% | +3.9% | +2.7% | +9.4% | — |
| May 15, 2024 | AMC | -1.09 | -0.82 | +24.8% | 3.74 | +0.8% | +0.0% | -11.8% | -12.8% | -14.2% | -12.8% | — |
| Mar 28, 2024 | AMC | -0.86 | -1.13 | -31.4% | 5.26 | +2.5% | -15.4% | -17.7% | -18.8% | -22.4% | -21.7% | — |
| Nov 14, 2023 | AMC | -1.41 | -0.95 | +32.6% | 1.92 | -3.1% | +5.2% | +0.0% | +29.7% | +26.6% | +17.2% | — |
| Aug 14, 2023 | AMC | -1.23 | -1.53 | -24.4% | 3.01 | -5.3% | -10.0% | -14.0% | -14.0% | -17.3% | -21.3% | — |
| May 15, 2023 | AMC | -1.28 | -1.35 | -5.5% | 5.27 | +0.0% | +10.4% | +6.8% | +1.3% | +12.1% | +29.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 27 | UBS | Maintains | Buy → Buy | — | $39.76 | $41.89 | +5.4% | -6.9% | -15.3% | -4.1% | +7.7% | +2.2% |
| Mar 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $39.76 | $41.89 | +5.4% | -6.9% | -15.3% | -4.1% | +7.7% | +2.2% |
| Feb 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.30 | $23.84 | -1.9% | -4.0% | -5.7% | -9.5% | -9.2% | -6.7% |
| Jan 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.71 | $27.55 | +3.1% | +5.0% | -3.2% | -3.9% | -8.2% | -2.4% |
| Nov 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.51 | $19.37 | -0.7% | +1.6% | -1.5% | +0.1% | +0.4% | +6.5% |
| Nov 17 | Chardan Capital | Maintains | Neutral → Neutral | — | $19.51 | $19.37 | -0.7% | +1.6% | -1.5% | +0.1% | +0.4% | +6.5% |
| Nov 11 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $18.49 | $20.02 | +8.3% | +6.2% | +9.5% | +2.1% | +5.5% | +7.2% |
| Oct 24 | JP Morgan | Upgrade | Neutral → Overweight | — | $17.11 | $19.14 | +11.9% | +9.2% | +10.1% | +12.5% | +10.6% | +23.0% |
| Oct 6 | Chardan Capital | Maintains | Neutral → Neutral | — | $15.06 | $15.09 | +0.2% | -2.7% | -5.5% | -4.0% | -10.0% | -21.2% |
| Sep 25 | Barclays | Upgrade | Underweight → Equal Weight | — | $15.49 | $16.34 | +5.5% | +1.2% | +2.0% | +2.1% | +5.7% | +1.7% |
| Aug 18 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $10.57 | $10.38 | -1.8% | +6.4% | -10.3% | -10.1% | -8.1% | -3.5% |
| Aug 14 | Barclays | Maintains | Underweight → Underweight | — | $8.62 | $9.44 | +9.5% | +16.5% | +22.6% | +30.5% | +10.0% | +10.2% |
| Aug 14 | JP Morgan | Upgrade | Underweight → Neutral | — | $8.62 | $9.44 | +9.5% | +16.5% | +22.6% | +30.5% | +10.0% | +10.2% |
| Mar 31 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $2.91 | $2.81 | -3.4% | -3.4% | -12.0% | -8.2% | -17.5% | -19.2% |
| Dec 9 | Jefferies | Upgrade | Hold → Buy | — | $7.83 | $8.92 | +13.9% | +29.6% | +27.7% | +14.2% | +6.9% | +8.2% |
| Nov 15 | Barclays | Maintains | Underweight → Underweight | — | $5.30 | $5.34 | +0.8% | +4.3% | +6.8% | +6.4% | +9.2% | +11.3% |
| Nov 15 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $5.30 | $5.34 | +0.8% | +4.3% | +6.8% | +6.4% | +9.2% | +11.3% |
| Sep 24 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $2.51 | $2.54 | +1.2% | +4.0% | +3.6% | +8.0% | +6.0% | +4.0% |
| Apr 4 | UBS | Maintains | Neutral → Neutral | — | $4.27 | $4.39 | +2.8% | -4.4% | -3.5% | +0.5% | +4.7% | +4.9% |
| Apr 1 | Barclays | Maintains | Underweight → Underweight | — | $5.26 | $5.39 | +2.5% | -15.4% | -17.7% | -18.8% | -22.4% | -21.7% |
| Dec 21 | UBS | Maintains | Neutral → Neutral | — | $2.79 | $2.93 | +5.0% | +5.4% | +9.0% | +9.0% | +13.6% | +16.1% |
| Nov 17 | Capital One | Upgrade | Equal Weight → Overweight | — | $1.92 | $2.10 | +9.4% | +29.7% | +26.6% | +17.2% | +25.0% | +39.1% |
| Jul 27 | UBS | Downgrade | Buy → Neutral | — | $3.24 | $3.28 | +1.2% | -10.5% | -11.4% | -7.7% | -7.4% | -2.5% |
| Jul 25 | JP Morgan | Downgrade | Neutral → Underweight | — | $3.95 | $3.74 | -5.3% | -8.1% | -18.0% | -26.6% | -27.3% | -24.3% |
| Jul 25 | Chardan Capital | Downgrade | Buy → Neutral | — | $3.95 | $3.74 | -5.3% | -8.1% | -18.0% | -26.6% | -27.3% | -24.3% |
| Jul 25 | Barclays | Maintains | Underweight → Underweight | — | $3.95 | $3.74 | -5.3% | -8.1% | -18.0% | -26.6% | -27.3% | -24.3% |
| Jul 24 | Jefferies | Downgrade | Buy → Hold | — | $7.29 | $3.03 | -58.4% | -45.8% | -50.2% | -55.6% | -60.2% | -60.6% |
| Jul 24 | Capital One | Downgrade | Overweight → Equal Weight | — | $7.29 | $3.03 | -58.4% | -45.8% | -50.2% | -55.6% | -60.2% | -60.6% |
| Apr 4 | JP Morgan | Maintains | Neutral → Neutral | — | $5.44 | $5.43 | -0.2% | -8.6% | -11.9% | -12.5% | -14.3% | -10.8% |
| Nov 14 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $7.56 | $7.52 | -0.5% | -4.1% | +6.0% | +1.6% | +0.7% | +0.3% |
| Nov 10 | Goldman Sachs | Maintains | Neutral → Neutral | — | $6.73 | $6.69 | -0.6% | +5.8% | +12.3% | +7.7% | +19.0% | +14.1% |
| Aug 15 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $12.20 | $12.05 | -1.2% | -1.2% | -3.2% | -5.0% | -6.6% | -14.3% |
| Aug 10 | Chardan Capital | Maintains | Buy → Buy | — | $10.92 | $10.91 | -0.1% | +14.5% | +7.8% | +11.7% | +10.3% | +8.2% |
| Aug 9 | Truist | Maintains | Buy → Buy | — | $11.11 | $10.90 | -1.9% | -1.7% | +12.5% | +5.9% | +9.8% | +8.5% |
| Aug 9 | Goldman Sachs | Maintains | Neutral → Neutral | — | $11.11 | $10.90 | -1.9% | -1.7% | +12.5% | +5.9% | +9.8% | +8.5% |
| Aug 2 | Citigroup | Downgrade | Neutral → Sell | — | $9.55 | $8.57 | -10.3% | -13.0% | -9.7% | -4.1% | +2.0% | +16.3% |
| May 24 | Goldman Sachs | Maintains | Neutral → Neutral | — | $6.85 | $6.78 | -1.0% | -4.8% | -2.5% | -1.9% | +1.0% | +5.7% |
| May 17 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $5.70 | $5.82 | +2.1% | +7.2% | +5.3% | +17.7% | +22.1% | +20.2% |
| May 11 | Goldman Sachs | Maintains | Neutral → Neutral | — | $5.45 | $5.33 | -2.2% | -7.5% | -1.7% | +1.5% | +4.6% | +12.1% |
| Apr 12 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $7.06 | $7.14 | +1.1% | -1.4% | +2.0% | -1.7% | -8.4% | -4.5% |
| Feb 24 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $9.86 | $8.76 | -11.2% | -7.0% | -10.5% | -12.4% | -10.3% | -10.2% |
| Feb 24 | Citigroup | Maintains | Neutral → Neutral | — | $9.86 | $8.76 | -11.2% | -7.0% | -10.5% | -12.4% | -10.3% | -10.2% |
| Feb 24 | JP Morgan | Downgrade | Overweight → Neutral | — | $9.86 | $8.76 | -11.2% | -7.0% | -10.5% | -12.4% | -10.3% | -10.2% |
| Feb 7 | Barclays | Maintains | Underweight → Underweight | — | $12.76 | $11.98 | -6.1% | -0.2% | +1.2% | +2.3% | -6.2% | -11.0% |
| Feb 2 | JP Morgan | Upgrade | Neutral → Overweight | — | $12.45 | $12.80 | +2.8% | -3.4% | -0.5% | +2.5% | +2.3% | +3.7% |
| Feb 1 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $11.74 | $12.09 | +3.0% | +6.0% | +2.5% | +5.5% | +8.7% | +8.5% |
| Jan 26 | Citigroup | Maintains | Neutral → Neutral | — | $11.99 | $12.40 | +3.4% | -8.0% | -13.4% | -8.8% | -2.1% | +3.8% |
| Jan 18 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $13.03 | $12.89 | -1.1% | -3.7% | -3.8% | -7.2% | -11.3% | -4.7% |
| Nov 11 | Citigroup | Maintains | Neutral → Neutral | — | $22.35 | $22.35 | +0.0% | +0.3% | +0.5% | -6.4% | -3.4% | -8.6% |
| May 11 | BMO Capital | Maintains | Market Perform → Market Perform | — | $17.68 | $15.20 | -14.0% | -7.6% | -10.2% | -9.2% | -4.9% | -4.3% |
No insider trades available.
8-K · 2.02
!! High
Kodiak Sciences Inc. -- 8-K 2.02: Earnings Results
Kodiak Sciences reported earnings results; investors should review the attached press release for detailed financial performance and operational updates affecting the company's stock valuation.
May 7
8-K
Unknown — 8-K Filing
Kodiak Sciences reported 2025 full-year results, signaling operational progress that investors should monitor for profitability trajectory and pipeline advancement in their ophthalmology focus area.
Mar 31
8-K
Unknown — 8-K Filing
Kodeira's Zenkuda showed compelling Phase 3 efficacy in diabetic retinopathy with statistically significant improvements across primary and secondary endpoints, substantially de-risking the drug candidate and supporting potential FDA approval prospects.
Mar 27
Data updated apr 25, 2026 5:49pm
· Source: massive.com